ASCO Guidelines for Surveillance of Stage II–III Colorectal Cancer Patients
Post‑operative CEA Monitoring Value
ASCO Surveillance Recommendations
Necessity of Imaging When CEA Is Normal
All facts are derived from ASCO guideline evidence (Journal of Clinical Oncology 2006) and reflect guideline‑level recommendations.
CEA Levels in Colorectal Cancer
CEA Production and Clinical Significance
- The American Society of Clinical Oncology (ASCO) guidelines indicate that CEA has high specificity but low sensitivity for identifying colorectal cancers, making it unsuitable for population screening 2
Factors Affecting CEA Levels
- Tumor stage and burden influence CEA levels, as stated by the American Society of Clinical Oncology (ASCO) 2
- Non-cancer related conditions such as gastritis, peptic ulcer disease, diverticulitis, liver diseases, COPD, diabetes, and inflammatory states can also affect CEA levels 3
CEA and Tumor Location
- The American Society of Clinical Oncology (ASCO) guidelines do not indicate a difference in CEA levels based on tumor location (right-sided vs. left-sided) 2, 4
CEA in Clinical Practice
- Preoperative CEA is an important independent prognostic variable in predicting outcomes, as recommended by the American Society of Clinical Oncology (ASCO) 2
- Elevated preoperative CEA (≥5 ng/mL) correlates with poorer prognosis regardless of tumor location, according to the American Society of Clinical Oncology (ASCO) 2
- Postoperative CEA monitoring is recommended every 3 months for patients with stage II or III disease for at least 3 years after diagnosis, as stated by the American Society of Clinical Oncology (ASCO) 2
- CEA is the marker of choice for monitoring metastatic colorectal cancer during systemic therapy, as indicated by the American Society of Clinical Oncology (ASCO) 3